方法：回顾性观察我院2016-01/03间收治的RVO继发黄斑水肿的患者22例22眼，3mo内给予3次玻璃体腔内注射康柏西普0.05mL(0.5mg)，比较治疗前后患者的视力变化情况，光学相干断层扫描(OCT)检查，眼底荧光造影(FFA)及眼底出血吸收情况。

结果：所选患者玻璃体内注射康柏西普在1wk，1、2、3mo后平均视力均有不同程度的提高，差异有统计学意义(P<0.05)。OCT图像显示黄斑中心凹视网膜厚度明显变薄，与治疗前相比差异具有统计学意义(P<0.05)。治疗后3mo检查FFA显示视网膜渗漏明显减轻，眼底出血明显吸收。

结论：玻璃体腔内注射抗VEGF药物康柏西普治疗RVO继发的黄斑水肿疗效肯定，但远期疗效及注射药物的频率尚需进一步观察与探讨。

METHODS: A total of 22 patients with macular edema secondary to retinal vein occlusion were treated in our hospital during January 2016 to Marth 2016. A total of 22 patients were given three intravitreal injections of Conbercept 0.05mL(0.5mg). Defore and after treatment, best-corrected visual acuity, fundus photography,fundus fluoreseein angiograph(FFA),optical coherence tomography(OCT)were examined.

RESULTS: A total of 22 patients were treated with intravitreal injection of Conbercept had different degrees of increase in the mean visual acuity at 1wk, 1, 2 and 3mo. The difference is statistically significant(P<0.05). OCT images show that the thickness of the central retinal thickness of the macular becomes thinner, and the difference is statistically significant(P<0.05). The FFA at 3mo showed a significant reduction in retinal leakage, obvious absorption of retinal hemorrhage.

CONCLUSION: Intravitreal injection of anti-VEGF drugs Conbercept is an effective way to treat macular edema secondary to retinal vein occlusion, it is worth to promot, but the long-term efficacy and drug injection frequency still need to study further.